In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.
•
Its main products address unmet medical needs in acute care, specifically pathogens like MRSA.
Torrent Pharmaceuticals | Emcure Pharmaceuticals | Barr Pharmaceuticals | Valeant Pharmaceuticals | Reata Pharmaceuticals | Millennium Pharmaceuticals | Anthera Pharmaceuticals | Quark Pharmaceuticals | Norwich Pharmaceuticals | Incepta Pharmaceuticals | Glenmark Pharmaceuticals | Cubist sculpture |
These investments include Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals, and Remon Medical Technologies.